Global Alzheimer's trial will study Roche, Lilly drugs

10/10/2012 | Reuters

Experimental Alzheimer's drugs from Roche Holding and Eli Lilly and Co. will be studied in a global trial of 160 patients with genetic indicators that they are prone to the disease. The study, set to begin next year, will include Roche's gantenerumab and Lilly's solanezumab, and a beta-secretase inhibitor from Lilly could be added.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Fort Worth, TX
Director, Senior Legal Counsel
Fort Worth, TX